A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC).

Reviewer: Walter Sall, MD
OncoLink
Ultima Vez Modificado: 15 de mayo del 2005

Translation for this article does not exist

Blogs

Eight Tips for Addressing Medical Billing Issues
by Christina Bach, MSW, LCSW, OSW-C
May 25, 2016